Literature DB >> 26718907

Myeloproliferative neoplasms: Morphology and clinical practice.

Tiziano Barbui1, Jürgen Thiele2, Alessandro M Vannucchi3, Ayalew Tefferi4.   

Abstract

In myeloproliferative neoplasms (MPNs), controversy persists regarding the usefulness and reproducibility of bone marrow (BM) features. Disagreements concerning the WHO classification are mainly focused on the discrimination between essential thrombocythemia (ET) and prefibrotic/early primary myelofibrosis (prePMF) and prodromal polycythemia vera (PV). Criticism mostly refers to lack of standardization of distinctive BM features precluding correct morphological pattern recognition. The distinction between WHO-defined ET and prePMF is not trivial because outcome is significantly worse in prePMF. Morphology was generally considered to be non-specific for the diagnosis of PV. Recent studies have revealed under-diagnosis of morphologically and biologically consistent PV.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 26718907     DOI: 10.1002/ajh.24288

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  9 in total

1.  Clinical features and next-generation sequencing landscape of essential thrombocythemia, prefibrotic primary myelofibrosis, and overt fibrotic primary myelofibrosis: a Chinese monocentric retrospective study.

Authors:  Lan Zhang; Xingnong Ye; Shuna Luo; Xiaofei Xu; Shengjie Wang; Keyi Jin; Yan Zheng; Xiaoqiong Zhu; Dan Chen; Jie Jin; Jian Huang
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-22       Impact factor: 4.553

2.  MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia.

Authors:  M Haider; Y C Elala; N Gangat; C A Hanson; A Tefferi
Journal:  Blood Cancer J       Date:  2016-10-21       Impact factor: 11.037

Review 3.  The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.

Authors:  Tiziano Barbui; Jürgen Thiele; Heinz Gisslinger; Hans Michael Kvasnicka; Alessandro M Vannucchi; Paola Guglielmelli; Attilio Orazi; Ayalew Tefferi
Journal:  Blood Cancer J       Date:  2018-02-09       Impact factor: 11.037

4.  Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data.

Authors:  Martin Schalling; Andreas Gleiss; Bettina Gisslinger; Albert Wölfler; Veronika Buxhofer-Ausch; Georg Jeryczynski; Maria-Theresa Krauth; Ingrid Simonitsch-Klupp; Christine Beham-Schmid; Jürgen Thiele; Heinz Gisslinger
Journal:  Blood Cancer J       Date:  2017-12-13       Impact factor: 11.037

5.  The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia.

Authors:  Yee Yee Yap; Kian Boon Law; Jameela Sathar; Ngee Siang Lau; Ai Sim Goh; Teng Keat Chew; Soo Min Lim; Padmini Menon; Yong Khee Guan; Azlan Bin Husin; Lily Lee Lee Wong; Lee Ping Chew; Sinari Salleh; Kim Yen Goh; Kin Wah Leong; Sen Mui Tan; Tee Chuan Ong; Su Hong Lim; See Guan Toh; Xavier Sim Yoon Han; Syed Carlo Edmund; Jenq Tzong Tan; Kian Meng Chang
Journal:  Exp Hematol Oncol       Date:  2018-12-17

6.  Therapeutic Plateletpheresis in Patients With Thrombocytosis: Gender, Hemoglobin Before Apheresis Significantly Affect Collection Efficiency.

Authors:  Hongqiang Jiang; Yanxia Jin; Yufeng Shang; Guolin Yuan; Dandan Liu; Jianfang Li; Cong Wang; Lu Ding; Xiqin Tong; Shishang Guo; Fayun Gong; Fuling Zhou
Journal:  Front Med (Lausanne)       Date:  2021-12-24

7.  ASXL1 mutations in Chinese patients with essential thrombocythemia.

Authors:  Yan-Bo Nie; Meng Sun; Colin K He; Man-Kai Ju; Fu-Ling Zhou; San-Yun Wu; Yi Zhou; Li Liu; Hui Shen; Ting-Ting Huang; Pan Liu; Ying Xu; Liang Shao; Xue-Lan Zuo
Journal:  Exp Ther Med       Date:  2018-03-09       Impact factor: 2.447

Review 8.  Cytokine Profiling in Myeloproliferative Neoplasms: Overview on Phenotype Correlation, Outcome Prediction, and Role of Genetic Variants.

Authors:  Elena Masselli; Giulia Pozzi; Giuliana Gobbi; Stefania Merighi; Stefania Gessi; Marco Vitale; Cecilia Carubbi
Journal:  Cells       Date:  2020-09-21       Impact factor: 6.600

Review 9.  The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms.

Authors:  Tanja Belčič Mikič; Tadej Pajič; Samo Zver; Matjaž Sever
Journal:  Int J Mol Sci       Date:  2021-03-25       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.